前立腺肥大症治療市場 - 世界の産業規模、シェア、動向、機会、予測：薬物治療別、外科治療別、エンドユーザー別、地域別、競合別、2020～2030年

世界の前立腺肥大症（BPH）治療市場は、2024年に15億3,000万米ドルと評価され、予測期間中のCAGRは8.75％で、2030年には25億1,000万米ドルに達すると予測されています。

世界の前立腺肥大症（BPH）治療市場は、高齢化人口の増加と泌尿器科の健康に対する意識の高まりに牽引され、着実な成長を遂げています。前立腺肥大症（BPH）は、前立腺の非がん性肥大であり、不快な排尿症状を引き起こし、生活の質に大きな影響を与えます。その結果、薬物療法から低侵襲の処置や手術に至るまで、効果的な治療オプションに対する需要が地域間で拡大しています。世界保健機関（WHO）の予測によると、2050年までに高齢者人口の約80％が低・中所得国に住むようになります。さらに、80歳以上の高齢者の数は2020～2050年の間に3倍に増え、約4億2,600万人に達すると予想されています。加齢は前立腺肥大症（BPH）の主要な危険因子であり、その有病率は高齢男性で著しく増加します。その結果、世界の高齢者人口の増加は、効果的な診断・管理ソリューションに対する需要の高まりとともに、今後数年間における前立腺肥大症治療市場の大幅な拡大を牽引するとみられます。

医療技術の進歩により、低侵襲性の治療法が導入され、回復に要する時間が短縮され、治療成績が向上したため、より多くの患者が適時に治療を受けるようになりました。医薬品分野は依然として市場の重要な部分を占めており、α遮断薬や5α還元酵素阻害薬が一般的に処方されています。一方、レーザー治療やその他のエネルギーベースの治療の台頭は、副作用の少ないより安全な代替手段を提供することで、外科手術の展望を再構築しつつあります。新興国におけるヘルスケアインフラの成長も、診断と治療へのアクセスを促進し、市場の成長をさらに後押ししています。ライフスタイルの変化、医療費の増加、泌尿器科における継続的な研究開発が、BPH管理の進化に寄与しています。患者の快適性と長期的な治療結果の改善に焦点を当てた世界のBPH治療市場は、認知度と技術革新の両方が進むにつれて拡大し続けるものと思われます。

主な市場促進要因

人口の高齢化

主な市場課題

先進治療の高コスト

主な市場動向

低侵襲治療へのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬物治療別（α遮断薬、5α還元酵素阻害剤、ホスホジエステラーゼ5阻害剤）
  • 外科治療別（経尿道的前立腺切除術（TURP）、前立腺尿道リフト（PUL）、前立腺摘出術、レーザー手術、経尿道マイクロ波技術（TUMT）、経尿道的前立腺針焼灼術（TUNA）、その他（レズム療法、ウロリフト療法））
  • エンドユーザー別（病院、診療所、外来手術センター、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024年）
• 市場マップ

第6章 北米の前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 地域別北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米の前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの前立腺肥大症（BPH）治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

第13章 臨床試験分析

第14章 競合情勢

• Boston Scientific Corporation
• Coloplast Corporation
• Teleflex Incorporated
• Olympus Corporation
• Glaxo Smith Kline PLC
• Eli Lily
• Abott Laboratories
• Medifocus Inc.
• Urologix, LLC
• Pfizer Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Benign Prostate Hyperplasia (BPH) Treatment Market was valued at USD 1.53 billion in 2024 and is expected to reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period. The global benign prostate hyperplasia (BPH) treatment market is experiencing steady growth, driven by the increasing prevalence of aging populations and rising awareness of urological health. BPH, a non-cancerous enlargement of the prostate gland, leads to uncomfortable urinary symptoms and significantly impacts quality of life. As a result, demand for effective treatment options-ranging from medication to minimally invasive procedures and surgery-is expanding across regions. According to World Health Organization (WHO) projections, by 2050, approximately 80% of the elderly population will live in low- and middle-income countries. Additionally, the number of individuals aged 80 and above is expected to triple between 2020 and 2050, reaching nearly 426 million. Age is the leading risk factor for benign prostatic hyperplasia (BPH), with its prevalence increasing significantly in older men. As a result, the growing global geriatric population is likely to drive substantial expansion in the BPH treatment market in the coming years, with heightened demand for effective diagnosis and management solutions.

Advancements in medical technology have introduced less invasive treatment methods with shorter recovery times and improved outcomes, encouraging more patients to seek timely intervention. The pharmaceutical segment remains a key part of the market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly prescribed. Meanwhile, the rise of laser therapies and other energy-based treatments is reshaping the surgical landscape by offering safer alternatives with reduced side effects. Growing healthcare infrastructure in emerging economies is also fostering access to diagnosis and treatment, further propelling market growth. The lifestyle changes, increased healthcare expenditure, and ongoing research and development in urology are contributing to the evolution of BPH management. With a focus on improving patient comfort and long-term results, the global BPH treatment market is poised to continue expanding as both awareness and technological innovation advance.

Key Market Drivers

Aging Population

The aging population is one of the most significant and influential drivers of the global benign prostate hyperplasia (BPH) treatment market. For instance, according to WHO 2025, global life expectancy at birth reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged 60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with the trend accelerating notably in developing regions. As men age, the likelihood of developing BPH increases substantially, making age a primary risk factor for the condition. BPH is characterized by the non-cancerous enlargement of the prostate gland, which commonly affects men over the age of 50. This physiological change occurs due to hormonal fluctuations, particularly the imbalance between testosterone and dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this leads to the gradual thickening and growth of the prostate, often resulting in urinary symptoms such as increased frequency, urgency, and incomplete bladder emptying.

Globally, improvements in healthcare, nutrition, and living standards have significantly extended life expectancy. This demographic shift means a larger proportion of the population is entering age brackets where BPH is more prevalent. Consequently, the demand for diagnostic, pharmaceutical, and surgical interventions is increasing. Healthcare systems, especially in developed countries, are seeing a growing burden of age-related conditions, with BPH being a leading urological issue among elderly men.

As people live longer and prioritize quality of life in older age, there is greater willingness to seek treatment for chronic but manageable conditions like BPH. The aging population is also more likely to be covered by healthcare insurance or public health systems, which further facilitates access to treatment. In emerging economies, increasing awareness among the elderly and improvements in medical infrastructure are similarly boosting diagnosis and treatment rates.

As this demographic trend continues, it is expected that the prevalence of BPH will rise, placing sustained demand on healthcare providers and driving innovation in less invasive, more effective treatment solutions. In this context, the aging population not only fuels market growth but also shapes the evolution of therapeutic strategies and healthcare delivery models for BPH.

Key Market Challenges

High Cost of Advanced Treatments

The high cost of advanced treatments poses a significant challenge to the growth and accessibility of the global benign prostate hyperplasia (BPH) treatment market. As medical technology evolves, newer treatment modalities such as laser therapies (e.g., HoLEP, GreenLight), water vapor therapy (Rezum), and prostatic urethral lift (UroLift) have emerged as preferred options due to their minimally invasive nature, shorter recovery times, and reduced side effects. However, these benefits come at a considerable financial cost. The equipment required for these procedures is often expensive, and so are the associated operational and maintenance costs, which are ultimately passed on to the patients or healthcare systems.

In many countries, especially those with limited healthcare funding or weak insurance infrastructure, the affordability of such advanced treatments becomes a major barrier. Patients in low- and middle-income regions may be forced to rely on older, more invasive procedures or pharmacological therapies, even when newer options would offer better outcomes. The private healthcare settings tend to dominate the availability of these innovations, making them inaccessible to individuals relying on public health services.

This economic disparity not only limits patient access but also discourages widespread adoption by healthcare providers due to the high initial investment. In addition, inconsistent or inadequate reimbursement policies in many regions further restrict the uptake of newer treatment modalities, particularly in outpatient settings. Without broader financial support or cost reduction strategies, the high cost of advanced BPH treatments remains a key obstacle to ensuring equitable access and scaling the market globally.

Key Market Trends

Shift Toward Minimally Invasive Procedure

The shift toward minimally invasive procedures is one of the most prominent trends shaping the global benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH treatment involved surgical interventions such as transurethral resection of the prostate (TURP), which, while effective, often required prolonged hospital stays, significant recovery time, and a higher risk of complications such as bleeding and sexual dysfunction. In contrast, minimally invasive procedures offer a less traumatic alternative with quicker recovery, fewer complications, and a reduced risk of side effects, making them increasingly popular among both patients and healthcare providers.

Technologies like laser therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic urethral lift (UroLift), and water vapor therapy (Rezum) have gained traction due to their ability to treat BPH with precision and efficiency. These treatments are performed using advanced instruments that can target the enlarged prostate tissue without the need for large incisions, leading to shorter hospital stays, faster recovery times, and less post-operative pain. As a result, many patients are opting for these procedures over traditional surgery, valuing the minimal downtime and reduced risks.

This shift also aligns with a broader trend in healthcare toward procedures that maximize patient comfort and minimize disruption to daily life. The growing popularity of minimally invasive treatments is driving innovation in the field, encouraging the development of more effective, less invasive therapies. As awareness of these alternatives spreads, the market for minimally invasive BPH treatments is expected to expand, offering more choices for patients and enhancing the overall treatment landscape.

Key Market Players

• Boston Scientific Corporation
• Coloplast Corporation
• Teleflex Incorporated
• Olympus Corporation
• Glaxo Smith Kline PLC
• Eli Lily
• Abott Laboratories
• Medifocus Inc.
• Urologix, LLC
• Pfizer Inc

Report Scope:

In this report, the Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• phosphodiesterase-5 inhibitors

Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

• Transurethral resection of the prostate (TURP)
• Prostatic Urethral Lift (PUL)
• Prostatectomy
• Laser Surgery
• Transurethral Microwave Technique (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostate Hyperplasia (BPH) Treatment Market.

Available Customizations:

Global Benign Prostate Hyperplasia (BPH) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
  • 5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
  • 5.2.3. By End User (hospitals and clinics, ambulatory surgical Centers, and Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Treatment
  • 6.2.2. By Surgical Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. By Region North America: Country Analysis
  • 6.3.1. United States Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Treatment
      • 6.3.1.2.2. By Surgical Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Treatment
      • 6.3.2.2.2. By Surgical Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Treatment
      • 6.3.3.2.2. By Surgical Treatment
      • 6.3.3.2.3. By End User

7. Europe Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Treatment
  • 7.2.2. By Surgical Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Treatment
      • 7.3.1.2.2. By Surgical Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Treatment
      • 7.3.2.2.2. By Surgical Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3.United Kingdom Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Treatment
      • 7.3.3.2.2. By Surgical Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Treatment
      • 7.3.4.2.2. By Surgical Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Treatment
      • 7.3.5.2.2. By Surgical Treatment
      • 7.3.5.2.3. By End User

8. Asia-Pacific Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Treatment
  • 8.2.2. By Surgical Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Treatment
      • 8.3.1.2.2. By Surgical Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Treatment
      • 8.3.2.2.2. By Surgical Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. India Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Treatment
      • 8.3.3.2.2. By Surgical Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Treatment
      • 8.3.4.2.2. By Surgical Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Treatment
      • 8.3.5.2.2. By Surgical Treatment
      • 8.3.5.2.3. By End User

9. South America Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Treatment
  • 9.2.2. By Surgical Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Treatment
      • 9.3.1.2.2. By Surgical Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Treatment
      • 9.3.2.2.2. By Surgical Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Treatment
      • 9.3.3.2.2. By Surgical Treatment
      • 9.3.3.2.3. By End User

10. Middle East and Africa Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Treatment
  • 10.2.2. By Surgical Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Treatment
      • 10.3.1.2.2. By Surgical Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Treatment
      • 10.3.2.2.2. By Surgical Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. South Africa Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Treatment
      • 10.3.3.2.2. By Surgical Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Type
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Boston Scientific Corporation
• 14.2. Coloplast Corporation
• 14.3. Teleflex Incorporated
• 14.4. Olympus Corporation
• 14.5. Glaxo Smith Kline PLC
• 14.6. Eli Lily
• 14.7. Abott Laboratories
• 14.8. Medifocus Inc.
• 14.9. Urologix, LLC
• 14.10.Pfizer Inc

15. Strategic Recommendations

16. About Us and Disclaimer